We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
ClinPharm Consulting Renamed to Kinetigen
News

ClinPharm Consulting Renamed to Kinetigen

ClinPharm Consulting Renamed to Kinetigen
News

ClinPharm Consulting Renamed to Kinetigen

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "ClinPharm Consulting Renamed to Kinetigen"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

ClinPharm Consulting, LLC (ClinPharm) has announced that the company is changing its name to Kinetigen, Inc., effective February 1, 2013.

All management, scientific, and operational components of Kinetigen remain the same as under ClinPharm, including the consulting firm’s focus on clinical pharmacology and pharmacokinetics.

The change to Kinetigen is a reflection of the impact that the company has made in the pharmaceutical industry and its evolution into a leading consulting firm in clinical pharmacology and pharmacokinetics.

In changing the company name, executive management determined that it was essential to develop a brand that will be easily identifiable and associated with the expertise and value that the company and its industry-leading consultants provide to clients.

“I’m thrilled to continue to build upon ClinPharm Consulting’s reputation and consultancy under our new name of Kinetigen” said Geoffrey Banks, Ph.D., Kinetigen President and CEO, adding, “The launch of Kinetigen is the keystone of our strategic growth initiative that will solidify our position as the go-to resource for clinical pharmacology and pharmacokinetics in the pharmaceutical industry”.

The consulting firm has grown organically over the past 5 years since the company was founded and recently added senior level consultants such as David Y. Mitchell, Ph.D., immediate past President of the American Association of Pharmaceutical Scientists (AAPS), Mark Sale, MD, former Global Director of Modeling and Simulation at GlaxoSmithKline (GSK), and Mark Bush, Ph.D., former Director of Pharmacokinetics at GSK.

“All of our services remain the same with the transition to Kinetigen,” said Bill Wargin, Ph.D., Kinetigen Executive Vice President & Chief Scientific Officer.

Dr. Wargin further explained “We have enhanced our SOPs and working practices, implemented more quality control procedures, and strengthened our training processes to ensure the highest quality product and services continue under Kinetigen that our clients have come to expect”.

Kinetigen’s services include:
• Rapid & robust pharmacokinetic analysis including non-compartmental, compartmental, and population pharmacokinetic methods with industry standard software (WinNonlin, NONMEM, Monolix, and NLME)
• Good Laboratory Practice (GLP) toxicokinetic analysis for determination of toxicokinetic parameters (including in-house QA capabilities and validated pharmacokinetic/ toxicokinetic analysis software)
• Unmatched interpretation of pharmacokinetic data from leading industry experts in pharmacokinetics
• Innovative model based drug development
• Clinical trial simulations
• Authoring clinical pharmacology and pharmacokinetic sections of regulatory submissions
• Assistance with regulatory briefing documents and meetings (e.g., FDA Pre-IND, EoP1, EoP2, pre-NDA, Type C meetings, etc.)
• Horizontal strategic planning across all phases of drug development
• Intelligent design of clinical studies from experts in clinical pharmacology and pharmacokinetics, including authoring clinical trial protocols and study reports
• Due diligence assessment for potential licensing of compounds

Advertisement